Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart failure

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

- PMLiVE

Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

A rapid round-up of pharma, biotech and healthcare news

- PMLiVE

Novo Nordisk appoints new general manager

Pinder Sahota also becomes the corporate vice president, UK

- PMLiVE

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

The candidate is expected to start a phase II trial in the coming months

- PMLiVE

Novo Nordisk’s semaglutide obesity trial hits the mark

The injection helped adults lose up to 13.8% of their body weight in a year

- PMLiVE

Novo launches $165m antimicrobial resistance initiative

The REPAIR Fund will support groups looking to combat antibiotic resistance

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

Sanofi reception

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

The offer comes at a 110% premium on the Belgian biopharma’s share price

- PMLiVE

Celixir cleared to start trial of stem cell therapy for heart failure

Previous trial demonstrated patients achieving 100% MACE free survival

- PMLiVE

Ablynx knocks-back Novo Nordisk’s second bid

Says the Danish pharma group “fundamentally undervalues” the company

- PMLiVE

Novo Nordisk makes improved €2.6bn offer for Ablynx

Goes back to the Belgian biopharma with a higher bid

Alexa: find Novo Nordisk voice-activated diabetes tech

Hitlab challenge selects patient education firm Lighthouse for $50,000 funding

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links